SSSGY (Sartorius AG) Interest Received

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SSSGY Sartorius AG SSSGY
77 GF Score
Price $43.93
GF Value $50.85
Valuation Modestly Undervalued
! 10 Warning Signs
View Full Analysis

What is Sartorius AG Interest Received?

Interest Received only applicable to companies reporting Cash Flow from Operations in direct method.

SSSGY
77GF Score
Sartorius AG SSSGY
Interest Received is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Sartorius AG (SSSGY) Overvalued in 2026?

Based on GuruFocus' analysis, Sartorius AG stock appears to be undervalued. The current stock price of $43.93 is trading 13.6% below its estimated GF Value™ of $50.85. GuruFocus considers Sartorius AG to be Modestly Undervalued.

Key valuation signals for SSSGY:

  • Interest Received:
  • GF Value™: $50.85 vs. price of $43.93 (13.6% below fair value)
  • GF Score™: 77/100 with 10 warning signs

No single metric tells the full story. See the SSSGY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Sartorius AG Business Description

Address Otto-Brenner-Strasse 20, Gottingen, NI, DEU, 37079
Sartorius AG is a leading provider of bioprocessing solutions. Its bioprocess division sells equipment and consumables for upstream and downstream manufacturing of biologic drugs and focuses on single-use technology. Its laboratory products and services division offers a wide range of products for laboratory use, including scales, pipettes, and filtration equipment. As of 2024, the bioprocess and LPS divisions contributed 80% and 20% of revenue, respectively. Bioprocess is housed in its subsidiary Sartorius Stedim Biotech, of which Sartorius AG has a 72% ownership and 83% voting control. The business is geographically diverse, with revenue across Europe, Middle East, and Africa (41% of 2024 sales), the Americas (36%), and Asia-Pacific (23%). We estimate China revenue to be around 10%.
77GF Score

Get the complete analysis for SSSGY

Interest Received is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$43.93
Price
$50.85
GF Value